论文部分内容阅读
目的探讨急性非ST段抬高性心肌梗死(NSTEMI)患者住院早期血浆N-末端脑钠肽前体(NT-proBNP)对其预后的影响。方法采用酶联免疫吸附法(ELISA)测定127例AMI患者住院早期血浆NT-proBNP水平,并与左室射血分数(LVEF)、1年主要不良心脏事件(MACE)对比分析。结果 NSTEMI早期患者血浆NT-proBNP水平为(375.3±98.4)pg/ml,与LVEF呈负相关(r=-0.447,P<0.01)。1年期发生MACE患者的血浆NT-proBNP水平明显高于未发生MACE者(463.4±58.3pg/mlvs246.6±103.9pg/ml,P<0.01)。结论 AMI患者血浆NT-proBNP水平与LVEF呈负相关。检测血浆NT-proBNP水平可预测AMI患者梗死面积、心功能及心血管事件的发生情况。
Objective To investigate the effect of early in-hospital plasma N-terminal pro brain natriuretic peptide (NT-proBNP) on the prognosis of patients with acute non-ST-segment elevation myocardial infarction (NSTEMI). Methods The plasma levels of NT-proBNP in 127 AMI patients were measured by enzyme-linked immunosorbent assay (ELISA), and compared with the left ventricular ejection fraction (LVEF) and 1-year major adverse cardiac event (MACE). Results The plasma level of NT-proBNP in early NSTEMI patients was (375.3 ± 98.4) pg / ml, which was negatively correlated with LVEF (r = -0.447, P <0.01). The plasma levels of NT-proBNP in 1-year MACE patients were significantly higher than those without MACE (463.4 ± 58.3 pg / ml vs 246.6 ± 103.9 pg / ml, P <0.01). Conclusion The plasma level of NT-proBNP in patients with AMI is negatively correlated with LVEF. Detecting plasma NT-proBNP levels can predict infarct size, cardiac function, and cardiovascular events in patients with AMI.